Exactly, capital raising is the biggest risk at this stage imo. It will only be more difficult to rasie fund in the future given cash rate is going up continously. Totally agree that we really need to partner asap, otherwise I can't imagine how low we'd have to go to raise money.
After dose selection, we will have 1170 participants to be screened for Para 002 stage 2 and Para 003 trials. This is a long long way that will incur significant trial costs. I really want to know how much money they need to run these large trials, and we do need a great CFO to work on these costs.
Ann: iPPS Demonstrates Multiple DMOAD Signals in Phase 2 Study, page-231
-
- There are more pages in this discussion • 156 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
30.0¢ |
Change
-0.010(3.23%) |
Mkt cap ! $104.9M | |||
| Open | High | Low | Value | Volume |
| 31.0¢ | 31.5¢ | 29.0¢ | $161.3K | 527.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 10756 | 30.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 31.0¢ | 62010 | 3 |
View Market Depth
| Last trade - 16.10pm 15/07/2024 (20 minute delay) ? |
| PAR (ASX) Chart |